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Abstract
Symptoms after human infection with the helminth Trichuris suis have not previously been described. Exposure to
helminths has been suggested as immune therapy against allergy and autoimmune diseases. We randomized adults with
allergic rhinitis to ingest a dose of 2500 T. suis eggs or placebo every 21 days for 168 days (total 8 doses) in a double-blind
clinical trial. In a previous publication, we reported a lack of efficacy and a high prevalence of adverse gastrointestinal
reactions. The aim of the present study was to present a detailed description of the adverse event data and post-hoc
analyses of gastrointestinal reactions. Adverse events and severity (mild, moderate, severe) were recorded daily by subjects,
classified by organ using MedDRA 10.0, and event rates compared between subjects on T. suis treatment vs. subjects on
placebo. T. suis-specific serum IgG antibodies were measured by a fluoroenzymeimmunoassay (Phadia ApS). During 163
days complete follow-up, subjects ingesting T. suis eggs (N= 49) had a three to 19-fold higher rate of events (median
duration, 2 days) with gastrointestinal reactions (moderate to severe flatulence, diarrhea, and upper abdominal pain)
compared with placebo subjects (N = 47). The highest incidence of affected subjects was seen from the first few days and
until day 42 (3rd dose): 63% vs. 29% for placebo; day 163: 76% vs. 49% for placebo. Seroprevalences increased concurrently
in the T. suis group: Day 59, 50%; day 90, 91%; day 170, 93%. The combined duration of episodes with onset before day 42
was#14 days in 80% of affected subjects. Age, gender, total IgE, and recent intestinal symptoms at baseline did not predict
gastrointestinal side effects. In conclusion, during the first 2 months, repeated ingestions of 2500 T. suis eggs caused
frequent gastrointestinal reactions lasting up to 14 days, whereas 4 months further treatment mainly provoked a subclinical
stimulation.
Trial registration: University hospital Medical Information Network trial registry Reg. no. R000001298, Trial ID
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Introduction
The whipworm Trichuris suis is a common mild intestinal
pathogen of pigs, which is able to establish temporarily in the
human caecum and colon [1,2]. Ingestions of live T. suis eggs was
reported to be effective in treating patients with inflammatory
bowel disease (IBD) in two clinical trials [3–6]. The rationale for
such therapy stems from the so-called hygiene hypothesis [6], and
observations of a reduced pathology in chronic helminth
infections, which is believed to be the results of immune-
suppression by regulatory T cells, cytokines (IL-10, TGF-b),
IgG4 replacing IgE, or other mechanism [7]. In experimental
studies, helminths can suppress disease activity in models of IBD as
well as of allergy, asthma, multiple sclerosis, type I diabetes, and
arthritis [8–11]. However, treatment of patients with allergic
rhinitis using T. suis infections, or patients with asthma or IBD
using hookworm infections, did not suppress disease activity in
recent clinical trials [12–14]. Withstanding the reported thera-
peutic effect of T. suis on IBD patients, similar treatment of other
chronic inflammatory diseases is relevant to put on trial [15].
Ingestion of live T. suis eggs has been advocated as safe to
humans. For example, the life cycle of T. suis is not associated with
auto-reinfection, direct person to person infection, aberrant
migration, or hypobiosis [1,3]. There has, however, not been
published any reports of adverse events other than case-reports
[16–19]. Recently we performed a randomized controlled clinical
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trial of T. suis therapy against allergic rhinitis in otherwise healthy
subjects [12]. We found no efficacy but T. suis antibodies (92%)
and eosinophilia (41%) which confirmed establishment of T. suis.
We reported that gastrointestinal reactions were common and
occurred at a higher prevalence in the T. suis group than the
placebo group. However, the prevalence data underlying this
conclusion was not described in detail. Our aim in this study was
to describe the adverse event data in detail (e.g. types of data
sources and distributions by organ groups), and to perform post-
hoc analyses to determine the incidence, severity, rate, duration
and potential risk factors for gastrointestinal symptoms after
human ingestion of whipworm T. suis eggs.
Methods
The protocol and original statistical plan for this trial, as well as
the CONSORT checklist are available as supporting information;
see checklist S1 and protocol S1.
Subjects and study design
The study was performed in accordance with the Declaration of
Helsinki [20] and Good Clinical Practice (GCP) and was approved
by an independent review board of the Danish Ethics Committees
(Reference no. H-KF-2006-4100). Written informed consent was
obtained before enrolment. The study was a randomized placebo-
controlled double-blinded single-center clinical trial conducted in the
capital of Denmark, as described in detail elsewhere [12]. Briefly,
enrolled subjects were age 18 to 65 years with grass pollen-induced
allergic rhinitis, no IBD, and no childbearing potential. Subjects
were randomized to receive eight treatments with placebo or T. suis
eggs with an interval of 21 days. The trial consisted of nine visits
scheduled over 168 days, spaced by 21 days (63) and including eight
treatments visits starting at visit one, and three blood sampling visits
scheduled at visit one (blood visit one), one of visit three to six (blood
visit two, scheduled during the grass pollen season), and at visit nine
(blood visit three). Enrolment (visit one) of subjects took two months.
Analyses of blood were performed as described elsewhere [12]
and included measurements of serum antibodies by a fluoroenzy-
meimmunoassay (ImmunoCAPTM, ISO 13485; Phadia ApS,
Allerød, Denmark), total histamine from cell lysis (RefLab ApS,
Copenhagen, Denmark) [21], and haematology (Copenhagen GP
Laboratory, ISO 17025, Copenhagen, Denmark). Seroconversion
for T. suis infection was defined as a T. suis-IgG level above the
mean of levels measured in a cohort of 15 non-atopic donors who
neither participated in the trial nor received T. suis eggs. The mean
was denoted the cut-off level.
Agent and intervention
The active agent consisted of embryonated T. suis eggs, which
were isolated from pigs by Parasite Technologies A/S, Copenha-
gen, Denmark, and processed to vials by Ovamed GmbH,
Barsbu¨ttel, Germany. Each vial was specified to contain 2500
embryonated eggs, or no eggs (placebo), in 15 ml liquid, to be used
for one oral treatment. With timely intervals of one to two months,
a bulk of liquid with eggs (five bulks in total) were filled onto vials
that were delivered to the trial site, as described elsewhere [12].
The numbers of embryonated eggs, counted by quality-controlled
microscopy, in randomly selected vials from bulk one to five were
2310, 2010, 2355, 2400, and 2400, respectively. Vials were
traceable to bulks by a labeling with blinded numbers indicating
subject and bulk number. Placebo was identically supplied and
formulated except that it contained no T. suis eggs. On scheduled
treatment dates (+/2 three days), administration was performed
by drinking directly from the vial. Subjects were instructed that the
vial’s content should be intaken on empty stomach.
Adverse events
Information on adverse events was recorded in diaries kept by
subjects daily, and in case report forms (CRF) kept by two doctors
and two nurses who evaluated events at each visit. The diaries and
CRFs were designed for the study with preprinted guide,
examples, baseline questions, and daily questions.
In the diary, subjects spontaneously (unsolicited) recorded the
name of any event of importance for their health (.100 recording
spaces). However, with the exception of ‘‘flatulence’’, ‘‘diarrhea’’,
and ‘‘pruritus ani’’ because these were preprinted in the diary to
systematically collect data on severity of symptoms that also occur
during pig T. suis or human T. trichiura infections. Subjects then
scored the severity of events by ticking off one of four numbers (0,
1, 2, 3) for the three weeks preceding 1st treatment, and daily
during trial. Subjects were guided only by the diary on how to
grade the numbers: ‘‘0 =No symptom, 1=mild symptom (easily
tolerated), 2 =moderate symptom (troubles activities), and 3= se-
vere symptom (hinders activities)’’. After completing a two-week
period subjects also ticked off the treatment they currently believed
they received (active, placebo, or ‘‘I do not know’’), and reasons
they believed so (‘‘I can guess it based on the doctor’’, ‘‘The
treatment affects me’’, ‘‘The treatment does not affect me’’, other).
In the CRF, the nurses recorded event name, start and end
date, maximum severity, and relatedness to treatment. This
specific information was obtained at the clinical visits, by the
doctor and then the nurse during interview with the subject and
inspection of his/hers diary. For guidance on which events should
be recorded in such detail, the doctor/nurse were first to record
for each visit whether the subject had experienced (1) moderate to
severe flatulence, diarrhea, and pruritus ani (yes/no), (2) serious
events (hospitalization) (yes/no), and (3) other events judged to be
important for the subject’s health (yes/no). If any of these
questions were answered in the affirmative, then the nurse should
record the events in detail. Because moderate to severe flatulence,
diarrhea, and pruritus ani were expected to occur spontaneously
without clinical importance, the nurses were guided to record such
events in detail only if they appeared unexpected, by way of
example ‘‘if a subject e.g. has more than seven days of moderate
diarrhea distributed over three weeks’’.
Using the medical software dictionary MedDRAH version 10.0
(International Federation of Pharmaceutical Manufacturers and
Associations, Geneva, Switzerland), Danish event names were assigned
a corresponding English Preferred Term (PT) from MedDRAH. The
PT events were included in analyses if treatment-emergent, i.e. not seen
in the three weeks before enrolment or worsened even if present in
those three weeks. The System Organ Class (SOC) for each event was
extracted from medDRAH. For groups or SOCs of events the
maximum daily severity was chosen for analyses.
Statistical analyses
Differences between the T. suis and placebo group in the rate of
adverse outcomes were evaluated by event rate ratios (RR) and
estimated by Cox regression using the PHREG procedure in SAS
(version 9.1.3., Cary, USA). Each subject was followed from start of
trial and end of each episode of the relevant adverse event until day
of the next relevant adverse event or their stop of diary, whichever
came first. Stop of diary was defined as the last day with complete
recording (no missing values) for allergic rhinitis symptoms and
medications (10 values) [12]. The date of the stop day corresponded
well with the last date memorized by electronic pocket peak-
flowmeters that all subjects blew into at least once every week. Inter-
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subject correlation was taken into account by using a variance
sandwich estimator. Test for effect modification by subject
characteristics were performed by including an interaction term in
the regression. Differences between the groups in duration of events
were tested by non-parametric log rank test using the LIFETEST
procedure in SAS. Within the T. suis group, differences between
trends in blood parameters over time in subjects with none or mild
vs. moderate or severe symptoms before the time of the blood
sampling were tested by linear regression using the GENMOD
procedure in SAS with inter-subject correlation taken into account
by Generalized Estimating Equation. Association between self-
evaluated and true treatment allocation was evaluated by chi-square
statistics. Missing values were disregarded. All tests were two sided
using a significance level of 5%.
Results
Study flow, subject characteristics and blinding
After randomization, allocation, and receival of first treatment
withT. suis eggs (N=50) and placebo (N=50), 1 subject in the T.suis
group discontinued the study due to move abroad, 2 subjects in the
placebo group dropped out due to no time/interest, and 1 subject in
the placebo group was withdrawn because his wife filled in the diary.
The study thus included 49 subjects on T. suis and 47 on placebo.
Subjects recorded diary for on average of 163 days (min. 68, Q1
167, median 168, Q3 168, max. 168) out of the 168 days the trial
lasted per subject. The characteristics of subjects were similar
between the treatment groups, as reported previously [12] and for
additional characteristics in Table 1. Treatment allocation was
blinded (i.e. to doctors, nurses, subjects, sponsor, and other study
personal) and the percentage of subjects who believed they received
T. suis (37% vs. 32% for placebo; P= 0.62), or the subset recording
they believed so based on the doctor (n= 1 vs. n= 0 for placebo),
was not significantly different between the treatment groups.
Gastrointestinal symptoms
Table 2 presents the rate ratio of self-recorded and doctor/
nurse-reported adverse events by organ class and treatment group.
Overall, only moderate to severe gastrointestinal symptoms
occurred consistently at a significantly higher rate in the T. suis
group when compared with the rate in the placebo group (Self-
recorded, RR 2.1, 95% CI 1.2–3.5; Doctor/nurse-recorded, RR 2.7,
95% CI, 1.5–5.2). Figure 1 presents the daily prevalence of
gastrointestinal symptoms by treatment group and gradings of
severity of gastrointestinal symptoms (mild, moderate, severe, and
any severity). Overall, mild gastrointestinal symptoms occurred at a
daily prevalence of about 10–20% in both treatment groups on the
majority of days during the trial (Figure 1A) while moderate and
severe symptoms were characteristic of the T. suis group (Figure 1B
and 1C). Table 3 presents the rate ratio of gastrointestinal adverse
events according to maximum severity and type by days and
treatment group. Overall, the rate of mild gastrointestinal
symptoms was not significantly different between the treatment
groups (Table 3). In contrast, the rate of moderate to severe
gastrointestinal symptoms in the T. suis group was significantly
higher than in the placebo group (Table 2 and 3).
The daily prevalence of gastrointestinal symptoms in the T. suis
group peaked once, notably 30 to 50 days after 1st treatment, and
then declined before day 63 (3rd treatment) (Figure 1). Until day
63, the T. suis group demonstrated significantly increased rates of
episodes with moderate to severe flatulence (RR 2.5; 95% CI 1.2–
5.4), diarrhea (RR 2.5; 95% CI 1.1–5.4), and upper abdominal
pain (placebo, none; T. suis, 29%; entire trial, RR 19.2; 95% CI
4.3–85.1) when compared with placebo, and this was not the case
after day 63 (overall RR 1.0; 95% CI 0.3–3.8) (Table 3). The
median duration of episodes (consecutive days) with the moderate
to severe gastrointestinal symptoms was 2.0 days over the entire
trial (vs. 1.3 days for placebo, P= 0.0006), and 2.5 days if onset
was before day 63 (vs. 1.0 day for placebo, P= 0.002) (subjects with
repeated episodes were represented by the mean duration of these
episodes). The combined duration of episodes with onset before
the prevalence peak (day 42) was #14 days in 80% of affected
subjects in the T. suis group. The median duration of severe
episodes over the entire trial was 1.4 days (vs. 1.0 day for placebo,
P= 0.12).
Figure 2 depicts the data underlying the above findings of a
higher rate, severity, and duration of episodes with moderate to
severe gastrointestinal symptoms in the T. suis group, and
demonstrates that the incidence (i.e. cumulative percentage) of
affected subjects increased from the first few days and until day 42.
Accordingly, after 21 days the cumulated percentage of subjects
who had their first episode of the symptoms (i.e. regardless of later
episodes, if any) was 27% vs. 15% for placebo (Figure 2). After 42
days, a total of 63% had the first episode of symptoms vs. 29% for
placebo. At the end of the study, the percentages were 76% vs.
49%, respectively (Figure 2). The corresponding cumulative
percentages for first episode of moderate to severe diarrhea were
12% vs. 6% after 21 days, 29% vs. 11% after 42 days, and 55% vs.
28% at end of study.
Treatment compliance
Figure 2 also presents treatment compliance for subjects who
reported moderate to severe gastrointestinal symptoms, marked as
X (treatment-related) and # (not treatment-related). No treat-
ments were discontinued because of mild gastrointestinal symp-
toms. A total of 12 subjects on T. suis (24%) started discontinuing
treatment because of moderate to severe gastrointestinal symptoms
that we judged to be treatment-related (vs 2% (n= 1) for placebo,
P,0.001). However, 8 of the subjects (16%) continued again after
Table 1. Baseline characteristics by treatment group in 100
subjects with grass-pollen induced allergic rhinitis in a
randomized placebo-controlled double-blind clinical trial of T.
suis for grass-pollen allergy, Denmark, 2008.
T. suis Placebo
N=50 N=50
Sex, n (%)
Male 48 (96) 47 (94)
Female 2 (4) 3 (6)
Caucasian, n (%) 50 (100%) 50 (100%)
Age (years)
Mean (SD) 35 (10) 39 (10)
Male 34 (9) 38 (10)
Female 60 (3) 51 (13)
Minimum-maximum 20–61 19–63
Allergic rhinitis 50 (100%) 50 (100%)
Duration of allergic rhinitis (years), mean (SD) 20 (11) 24 (12)
Body mass index (kg/height2), median 24.7* 25.6
Minimum-maximum 19.5–39.2* 19.7–44.3
Total IgE (kU/l), median 72.9 70.3
Minimum-maximum 20.7–620.6 13.5–1206
*One subject was missing information on height.
doi:10.1371/journal.pone.0022346.t001
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pausing one treatment only, and 4 of the subjects (8%)
discontinued treatment the rest of the study (but continued
symptom diary, 2 a few months further, 2 until end) (see figure 2).
No other subjects in the study had treatment-related discontinu-
ation of treatments. Because of reasons unrelated to treatment, 6
subjects on T. suis (4 had moderate to severe symptoms, thus
shown in figure 2) and 3 subjects on placebo (2 shown in figure 2)
discontinued one or more treatments (12% vs. 6%, P= 0.32),
however, 2 of the 6 subjects on T. suis had previously discontinued
one treatment due to treatment-related gastrointestinal symptoms
(both shown in figure 2). The exact distribution of the total
number of treatments received was as follows (ds, doses): T. suis
group (N= 49): 8 ds, n = 32 (65%); 7 ds, n = 9 (18%); 6 ds, n = 1
(2%); 5 ds, n = 3 (6%); 4 ds, n = 1 (2%); 3 ds, n = 1 (2%); 2 ds,
n = 2 (4%). Placebo group (N= 47): 8 ds, n = 41 (87%); 7 ds, n = 4
(9%); 6 ds, n = 2 (4%).
Potential risk factors for gastrointestinal symptoms
Table 4 shows potential risk factors for gastrointestinal
symptoms before day 63. Overall, the rate of first moderate to
severe gastrointestinal symptoms in the T. suis group vs. placebo
was not modified by the bulk filled on the vials for the 1st and 2nd
treatment (P = 0.31); sex (P= 0.23); age (P = 0.72); body mass
index (P= 0.52); duration of allergic rhinitis (P = 0.65); allergic co-
morbidities including asthma, birch-pollen allergy, atopic derma-
titis, food allergy, or symptomatic cross-reactions to allergens
(P = 0.29); allergy of mother and/or father (P = 0.76); total IgE
level (P = 0.77); any gastrointestinal morbidity in the three weeks
before 1st treatment (P = 0.15); pets ever in household (P= 0.06);
and current or ever smoking (yes vs. no, P= 0.92 and 0.41). The
results presented in this paragraph were similar for entire trial and
for diarrhea (data not shown).
Gastrointestinal symptoms and blood analyses
To investigate whether self-reported gastrointestinal symptoms
were related to objective measurements, results of blood analyses
were stratified by the two significantly different subgroups of
moderate/severe and none/mild gastrointestinal symptoms
(Table 5 and Figure 3).
Figure 3 demonstrates serum level of T. suis-IgG over time in
the T. suis group according to maximum severity of gastrointes-
tinal symptoms before consecutive blood sampling dates (Data is
not shown for the placebo group, because after first treatment any
T. suis-response were significantly higher in the T. suis group than
the placebo group) [12]. Overall, the T. suis-IgG level in the T.
suis group (Figure 3, and Table 5) increased over time
Table 2. Rate ratios (RR) for first adverse event according to System Organ Class by treatment group in a randomized double-blind
clinical trial of T. suis and placebo, Denmark, 2008.
First adverse events recorded by subject First adverse event recorded by doctors/nurses
Any
severity
Moderate
to severe
Any
severity
Moderate
to severe
T. suis Placebo T. suis Placebo
N=49 N=47 N=49 N=47
n (%) n (%) RR (95% CI) RR (95% CI) n (%) n (%) RR (95% CI) RR (95% CI)
Any adverse event 44 (90) 40 (85) 1.2 (0.8–1.8) 1.2 (0.6–2.4) 43 (88) 36 (77) 1.6 (1.0–2.5) 1.8 (1.1–3.0)
Gastrointestinal disorders 43 (88) 34 (72) 1.4 (0.9–2.2) 2.1 (1.2–3.5) 37 (76) 24 (51) 2.0 (1.2–3.4) 2.8 (1.5–5.2)
Nervous system disorders 15 (31) 19 (40) 0.7 (0.4–1.4) 0.8 (0.4–1.7) 18 (37) 18 (38) 0.9 (0.5–1.7) 0.8 (0.3–2.1)
Respiratory, thoracic and
mediastinal disorders
12 (25) 7 (15) 1.8 (0.7–4.6) 1.7 (0.6–4.7) 11 (22) 9 (19) 1.2 (0.5–2.9) 1.1 (0.4–3.4)
Skin and subcutaneous disorders* 10 (20) 2 (4) 5.2 (1.1–23.5) 3.5 (0.7–16.7) 9 (18) 3 (6) 3.1 (0.8–11.4) 3.9 (0.4–35.2)
Musculoskeletal and
connective disorders{
7 (14) 2 (4) 4.1 (0.8–20.2) 7.1 (0.8–60.0) 7 (14) 5 (11) 1.3 (0.4–4.2) 2.4 (0.5–12.6)
General disorders and
administration site conditions{
5 (10) 14 (30) 0.3 (0.1–0.8) 0.6 (0.2–1.7) 5 (10) 12 (26) 0.4 (0.1–1.1) 1.0 (0.3–3.4)
Infections and infestations{{ 4 (8) 3 (6) 1.3 (0.3–5.9) 1.3 (0.3–5.9) 5 (10) 4 (9) 1.2 (0.3–4.6) 1.5 (0.2–8.9)
Injury, poisoning, and
procedural complications
4 (8) 3 (6) 1.3 (0.3–5.8) 1.9 (0.4–10.6) 3 (6) 3 (6) 1.0 (0.2–4.8) 1.9 (0.2–21.4)
Eye disorders 3 (6) 2 (4) 1.4 (0.2–8.5) {{ 3 (6) 3 (6) 1.0 (0.2–4.8) {{
Other System Organ Classes
(,5% in each group)
4 (9) 4 (8) 1.0 (0.2–3.8) 1.3 (0.3–5.7) 7 (14) 5 (11) 1.3 (0.4–4.2) 1.9 (0.4–10.6)
Indicated below, events recorded in the T. suis group (by subjects, n = x; doctors/nurses, n = xx) and placebo group (by subjects, n = y; doctors/nurses, n = yy) including
multiple types in a subject:
*Eczema (x = 3, xx = 3, y = 1), skin irritation (x = 3, xx = 3, yy = 1), impetigo (x = 1, xx = 1), rash papular (x = 1, xx = 1), rash (x = 1), sun eczema (x = 1, xx = 1), urticaria (x = 1,
xx = 1, y = 1, yy = 1), acne (yy = 1).
{Arthralgia (x = 1, xx = 2), myalgia (x = 1, xx = 1, yy = 1), pain in extremity (x = 1, xx = 1), back pain (x = 2, xx = 3, yy = 3), rib fracture (x = 1, xx = 1), wrist fracture (x = 1, xx = 1),
musculoskeletal discomfort (x = 1, y = 1, yy = 1), abscess limb (y = 1).
{Discomfort (x = 1, xx = 1, y = 1, yy = 1), fatigue (x = 2, xx = 2, y = 7, yy = 5), feeling of body temperature change (x = 2, xx = 2, y = 7, yy = 7), hunger/stomach acid (y = 1,
yy = 1), application site reaction (y = 1, yy = 1, unrelated to T. suis treatment), alcoholic hangover (y = 1), skin tenderness (yy = 1).
{{Enterobiasis (possible pinworm, xx = 1), herpes zoster (xx = 1), skin infection (yy = 1), ear infection (y = 0), influenza (x = 3, xx = 2, y = 1, yy = 1), chlamydial infection
(xx = 1), pneumonia (y = 1,yy = 1), pneumonia viral (yy = 1), varicella (x = 1, xx = 1), and sweating fever (x = 1, xx = 1).
{{RR could not be calculated because of zero cases in ether or both treatment groups.
doi:10.1371/journal.pone.0022346.t002
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(Ptrend,0.0001). However, subjects who had had mild or no
symptoms exhibited a significantly larger increase in levels
(Pdifference in trend = 0.02) and higher final levels than subjects
who had moderate or severe symptoms (Pday 59(1.period) = 0.71, 7.4
vs. 8.9 mgA/liter; Pday 90 (2. period) = 0.79, 21.0 vs. 14.6 mgA/liter;
Pday 170(End) = 0.0001, 43.8 vs. 27.1 mgA/liter). For T. suis-IgG4,
overall levels also increased over time (Ptrend,0.0001) and
again subjects with mild or no symptoms had significantly
higher final levels (Pdifference in trend = 0.07, Pday 59(1.period) = 0.37,
Pday 90(2.period) = 0.32, Pday 170(End) = 0.002). For T. suis-IgA,
T. suis-IgE and eosinophil counts, overall levels increased
moderately and significantly over time, as reported previously
[12], and the two symptom subgroups were not significantly
different (Table 5). All results presented in this paragraph were
not materially different when restricting analyses to subjects who
received all 8 treatments with T. suis ova (data not shown).
Using the data points in figure 2 and a cut-off value of
5.1 mgA/L (95% CI 3.9–6.2), determined previously in 15 non-
atopics [12], to identify T. suis-IgG seroconverted subjects, then
seroprevalences over four, not only three, time points was
calculated for the T. suis group: 0% (0/0) at day 1, 50% (9/18)
at day 59, 91% (30/33) at day 90, and 93% (42/45) at day 170.
The seroprevalences are for the T. suis group only, because no
significant T. suis-specific response was seen in the placebo group
(2 false-negative at baseline, vs. 1 false-positive in the T. suis group
at baseline; sensitivity 96% and specificity 98%).
Finally, total IgE, non-specified IgE (i.e. total IgE minus T. suis-,
grass-, and birch-IgE in each subject) and total blood histamine (a
proxy measure for blood basophils) and other hematology than
eosinophil counts (e.g. lymphocyte counts) were not different from
placebo at any time point (data not shown) and the T. suis group
was therefore not studied further for these parameters, except as
shown in table 5.
Discussion
The present study demonstrated that controlled infection of
humans with the pig parasite T. suis caused a three to 19-fold
increased rate of episodes with flatulence, diarrhea, and abdominal
pain. The first ingestion of a dose of 2500 T. suis eggs, and/or
ingestion of the next dose 21 days later, caused these transitory
side effects to appear during the first 1K month (42 days), because
there was no similar effect after later intake of eggs. The repeated
infections occurred along with increasing T. suis-specific IgG,
Figure 1. Daily prevalence of subjects who reported gastrointestinal symptoms. (A) by number of days participating in a randomized
double-blind clinical trial of three-weekly ingestions of infective T. suis eggs (N= 49, red/bold line) and placebo (N= 47, blue/grey line), along with
corresponding figures for subjects who reported severe (B), moderate (C) and mild (D) gastrointestinal symptoms, Denmark, 2008. Vertical lines
represent days of clinic visits (three-weekly) when subjects were to ingest 2500 live T. suis eggs or placebo except on visit day 168 (total 8 doses).
doi:10.1371/journal.pone.0022346.g001
Table 3. Rate ratio (RR) of gastrointestinal adverse events according to maximum severity and type by days and treatment group
in a randomized double-blind clinical trial of T. suis and placebo, Denmark, 2008.
Before day 63 On or after day 63 Entire trial
T. suis Placebo T. suis Placebo T. suis Placebo
N=49 N=47 N=49 N=47 N=49 N=47
N (%) n (%) RR (95% CI) n (%) n (%) RR (95% CI) n (%) n (%) RR (95% CI)
Total 38 (78) 30 (64) 1.3 (0.8–2.1) 36 (73) 27 (57) 1.5 (0.4–5.2) 43 (88) 34 (72) 1.3 (0.8–2.1)
Any mild 37 (76) 28 (60) 1.4 (0.9–2.3) 32 (65) 27 (57) 0.5 (0.1–1.9) 40 (82) 34 (72) 1.5 (0.9–2.4)
Any moderate 28 (57) 19 (40) 1.7 (1.0–3.1) 21 (43) 14 (30) 2.1 (0.5–8.0) 34 (69) 22 (47) 2.0 (1.2–3.5)
Any severe 14 (29) 4 (9) 4.0 (1.4–12.1) 8 (16) 4 (9) 1.7 (0.4–6.9) 19 (39) 7 (15) 3.2 (1.3–8.1)
Moderate to severe 31 (63) 20 (43) 1.9 (1.1–3.3) 22 (45) 14 (30) 2.0 (0.5–8.0) 37 (76)** 23 (49)** 1.9 (1.1–3.3)
Flatulence 20 (41) 9 (19) 2.5 (1.2–5.4) 10 (13) 6 (13) 1.0 (0.1–15.2) 21 (43) 10 (21) 3.4 (1.4–8.1)
Diarrhea 19 (39) 9 (19) 2.5 (1.1–5.4) 15 (31) 7 (15) 2.0 (0.6–6.7) 27 (55) 13 (28) 2.8 (1.4–5.6)
Abdominal pain 14 (29) 0 (0) - 7 (14) 2 (4) 1.0 (0.1–6.9) 16 (33) 2 (4) 19.2 (4.3–85.1)
Pruritus ani 5 (10) 7 (15) 0.7 (0.2–2.1) 2 (4) 5 (11) 1.0 (0.1–15.5) 6 (12) 8 (17) 1.0 (0.3–3.6)
Other* 5 (10) 5 (11) 1.0 (0.3–3.2) 6 (12) 1 (2) 3.0 (0.3–28.2) 8 (16) 6 (13) 2.1 (0.7–6.2)
Diarrhea, abdominal pain, and/or flatulence
Total 38 (78) 26 (55) 1.7 (1.1–2.8) 33 (67) 21 (45) 0.6 (0.1–2.5) 41 (84) 31 (66) 1.6 (0.9–2.7)
Any mild 36 (73) 25 (53) 1.7 (1.0–2.7) 28 (57) 21 (45) 0.2 (0.0–1.6) 37 (76) 30 (64) 1.8 (1.1–3.2)
Any moderate 26 (53) 11 (23) 2.9 (1.4–5.8) 18 (37) 10 (21) 1.0 (0.3–3.9) 30 (61) 15 (32) 2.9 (1.5–5.7)
Any severe 14 (27) 3 (6) 5.1 (1.5–17.4) 6 (12) 2 (4) 4.1 (0.5–35.7) 17 (35) 4 (9) 6.5 (2.1–20.1)
Moderate to severe 29 (59) 12 (26) 3.1 (1.6–6.0) 19 (38) 10 (21) 1.0 (0.3–3.8) 33 (67) 16 (34) 2.8 (1.4–5.4)
*Include events occurring in less than 5% of subjects on T. suis (n = x), and placebo (n = y): Nausea (x = 3, y = 1), stomach discomfort, (x = 3, y = 2), constipation (x = 1),
haemoroids (x = 1), lip dry (y = 1), tooth ache (x = 1, y = 2), oesophagal discomfort (y = 1), oesophagal pain (x = 3, y = 2), vomiting (y = 1), dysphagia (x = 1), gastroenteritis
viral (x = 1).
**Among those who believed they received T. suis eggs (vs. the remaining subjects), the corresponding percentage was 83% (vs. 71%) in the T. suis group and 53% (vs.
47%) in the placebo group. If the allocation was disregarded, the percentage was 70% among those who believed they received T. suis eggs and 59% among the
remaining subjects.
doi:10.1371/journal.pone.0022346.t003
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IgG4, IgA, and IgE levels. However, the T. suis-IgG-response
developed slower in subjects who had had gastrointestinal
reactions – an observation we speculate could be due to expulsion
of T. suis larvae during initial exposure in some humans.
Gastrointestinal side effects were also reported in a recent
clinical phase I trial that evaluated the safety of T. suis treatment in
five multiple sclerosis (MS) patients [15]. The authors used
comparable egg dose (2500) and interval (14 days) over three
months (total 6 doses), and three of the five subjects experienced
the onset of mild gastrointestinal symptoms (FDA scale grade 1, no
interference with activities of daily living such as school or work,
2–3 loose stools per day) at about 30 days after the first dose of T.
suis ova. Spontaneous resolution of these symptoms occurred after
6, 1, and 4 days in each subject. These results are compatible with
our observations, although based on smaller numbers and
information collected not daily but monthly at clinical visits. In
contrast to both reports, no side effects were observed in three
earlier IBD studies which used similar egg dose (2500) and interval
(21 or 14 days) and improved gastrointestinal symptoms in
Crohn’s disease and ulcerative colitis patients [3–5,22]. A
significant change in disease activity, e.g. patient-reported stool
frequency, was reported to start as early as 1K–3 months after 1st
dose [4], which is not as early as diarrhea due to T. suis in our
allergic rhinitis patients. Possible explanations for the lack of
Figure 2. Incidence of gastrointestinal symptoms after three-weekly ingestions of infective T. suis eggs by 49 subjects, and placebo
by 47 subjects, in a randomized placebo-controlled double-blinded clinical trial, Denmark 2008. Vertical lines represent days of clinic
visits (three-weekly) when subjects were to ingest 2500 live T. suis eggs or placebo except on visit day 168 (total 8 doses). Each horizontal thin line
represents a subject. Episodes of each subject are indicated by grey (moderate) and black (severe) horizontal thick lines. ‘‘X’’, the subject ingested no
eggs/placebo due to gastrointestinal symptoms; ‘‘#’’,the subject ingested no eggs/placebo due to reasons unrelated to the intervention; ‘‘O’’, the
subject stopped recording diary of symptoms before end of trial.
doi:10.1371/journal.pone.0022346.g002
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gastrointestinal side effects could be that the already increased
stool frequency in IBD patients made it difficult to detect
temporary T. suis-induced changes in stool frequency, or that
the IBD patients received immune-suppressive drugs which then
concealed early intestinal side effects. However, although similar
information was collected in the IBD studies and the present study
(stool frequency, diarrhea), the IBD study with the most detailed
temporal data presented results using a 2-weekly disease activity
index (the Simple Index) with multiple components (stool
frequency, urgency of defecation, blood in stool, general well-
Table 4. Rate ratio of first moderate to severe gastrointestinal symptoms (before day 63) within strata of characteristics in a
randomized placebo-controlled double-blind clinical trial of T. suis for grass-pollen allergy, Denmark, 2008.
T. suis Placebo RR (95% CI)
P-value for RR-
modification by strata
Overall 31/49 (63%) 20/47 (43%) 2.1 (1.2–3.5)
T. suis egg or placebo bulk filled onto vials intaken at*
visit 1; visit 2
Bulk 1; bulk 2 or 3 11/13 (85) 5/12 (42) 4.2 (1.4–12.3)
Bulk 2; bulk 3 9/17 (53) 7/18 (39) 1.7 (0.6–4.6) P = 0.31
Bulk 3; bulk 3 or 4 11/19 (58) 8/17 (47) 1.3 (0.5–3.1)
Sex
Male 30/47 (64) 18/45 (40) 2.1 (1.1–3.7) P = 0.23
Female K (50) 2/2 (100) 0.6 (0.1–7.0)
Age
20–32 years 17/25 (68) 6/15 (40) 2.0 (0.8–5.1) P = 0.72
33–63 years 14/24 (58) 14/32 (44) 1.7 (0.8–3.7)
BMI (kg/height2){{
Normal 17/27 (63) 9/17 (53) 1.6 (0.7–3.6) P = 0.52
Overweight/obese 14/22 (64) 11/29 (38) 2.1 (0.9–4.6)
Duration of allergic rhinitis (years)
3–17 years 17/25 (68) 7/17 (41) 2.2 (0.9–5.3) P = 0.65
18–53 years 14/24 (58) 13/30 (43) 1.7 (0.8–3.6)
Allergic comorbidity{
No 4/9 (44) 4/8 (50) 0.9 (0.2–3.8) P = 0.29
Yes 27/40 (68) 16/39 (41) 2.2 (1.2–4.1)
Allergy of mother and/or father
No 15/23 (65) 11/27 (41) 2.2 (1.0–4.7) P = 0.76
Yes 16/26 (62) 9/20 (45) 1.7 (0.7–3.8)
Total IgE (kU/l) at baseline
Low (,100) 13/19 (68) 10/19 (53) 1.8 (0.8–4.1) P = 0.77
High (100–1200) 18/30 (60) 10/28 (36) 2.1 (1.0–4.5)
Gastrointestinal morbidity{
No 16/27 (59) 7/26 (27) 3.02 (1.2–7.4) P = 0.15
Yes, recent 15/22 (68) 13/21 (62) 1.23 (0.6–2.7)
Pets ever in household
None 15/22 (68) 12/17 (71) 1.1 (0.5–2.3) P = 0.06
Any 16/27 (59) 8/30 (27) 3.0 (1.3–7.1)
Smoking
No 20/30 (67) 10/27 (37) 2.3 (1.1–5.0) P = 0.41
Ever 11/19 (58) 10/20 (50) 1.5 (0.6–3.4)
No 27/43 (63) 17/42 (41) 1.9 (1.1–3.6) P = 0.92
Current 4/6 (67) 3/5 (60) 1.8 (0.4–8.0)
*The numbers of embryonated eggs, counted by quality-controlled microscopy, in randomly selected vials from bulk one to five were 2310, 2010, 2355, 2400, and 2400,
respectively. Due to small numbers some bulk groups were joined.
{Included birch-pollen induced allergic rhinitis (defined as subjects having birch-IgE$0.7 kUA/l, birch-SPT$3 mm, and reporting significant symptoms to birch-pollen in
$1 of the last 4 years), food allergy, symptomatic cross-reactions to allergens, a diagnosis of asthma, or a diagnosis of atopic eczema.
{{Overweight/obese defined as BMI$25. One subject was missing information on height.
{Subjects with any diarrhea, flatulence, pruritis ani, or other gastrointestinal disorder 3 weeks before trial (n = 43 of 96).
doi:10.1371/journal.pone.0022346.t004
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being, and extracolonic features), and is therefore not directly
comparable.
Despite the lack of side effects in clinical trials of T. suis prior to
the present (i.e. the IBD studies), we suspected there would be
some intestinal reactions during infestations with whipworms, and
therefore implemented standard questions to increase detection.
We did this as a supplement to the spontaneous reporting of
adverse events, and anticipated that it might increase awareness
of adverse events, although not differently between treatment
groups. Compatible with this there was a similar rate of mild
gastrointestinal symptoms by treatment group, but in the T. suis
group we detected a significantly higher rate and duration of more
severe (i.e. moderate to severe) gastrointestinal symptoms, which
we therefore interpreted as side effects and not increased
awareness. Importantly, rates of side-effects were also increased
for rates of first episode of symptoms, i.e. thus excluding bias from
awareness due to previous symptoms from T. suis. In addition, we
evaluated whether subjects guessed their treatment allocation
despite the blinding, and found no statistical evidence to support
this.
We did not obtain a definitive diagnosis of flatulence, diarrhea,
and abdominal pain, for example by using systematic examina-
tions or sampling of stools. This was simply because the side-effects
were unexpected and ethical permission for further systematic
examination of subjects could not have been obtained in due time.
However, as illustrated in figure 2, the symptoms were transitory,
and therefore in fact difficult to observe with the three-week visit
interval. For example, in three cases we recorded our results of
abdominal palpations at their visit at the clinic and found nothing
abnormal, despite that the subjects had had weeks with diarrhea
and abdominal pain. Overall however, we inquired systematically
about, e.g., diarrhea in a follow-up questionnaire one year after
the study, and found that stools had never been bloody, always
watery (75% responded in each treatment group, data not shown).
We also found further support that the side-effects were
clinically significant, when we considered the repeated evaluations
at visits by doctor, nurse and subject, of any unusual moderate to
severe gastrointestinal symptoms since last visit. Based on these
blinded evaluations, it was decided in 13 cases to pause next
treatment (see figure 2), and it turned out after the unblinding of
Table 5. Median value of blood parameters over time according to severity of gastrointestinal symptoms after ingestion of
whipworm T. suis eggs (N = 49) in a randomized double-blind clinical trial of T. suis for grass-pollen allergy, Denmark, 2008.
Grass pollen season{
Start 1st period 2nd period End
None Moderate None Moderate None Moderate
P-value (time,
severity){
Mild Severe Mild Severe Mild Severe
N=49 n=8 n=10 n=8 n=25 n=12 n=33
(different from placebo{{)
T. suis-IgG (mgA/l) 1.90 7.4 8.9 21.0* 14.6 43.8* 27.1 0.02
T. suis-IgE (kUA/l) ,0.01 0.04 0.03 0.28 0.23 2.95* 1.35 0.07
T. suis-IgE (kUA/l) ,0.01 0.04 0.03 0.12 0.18 0.29 0.35 0.70
T. suis-IgA (mgA/l) 2.85 2.76 3.01 3.70 3.84 3.47 3.03 0.87
Eosinophil count (109/l) 0.20 0.68 0.61 0.57 0.48 0.34 0.45 0.12
(not different from placebo{{)
Total IgE (kU/l) 70.9 62.3 70.4 100.0 139.1 96.0 123.5 0.86
Non-specified IgE (kU/l){{ 53.1 50.4 42.5 87.3 109.7 80.8 78.1 0.82
Total histamine (ng/ml) 100 146 101 109 139 77 109 0.08
Basophil count (109/l) 0.03 0.06* 0.03 0.04 0.04 0.04 0.05 0.61
Haemoglobulin (mmol/l) 9.2 9.3 9.3 9.5 9.3 9.2 9.2 0.55
Leucocyt count (109/l) 6.00 7.70* 6.00 6.80 5.95 6.55 6.15 0.78
Lymphocyt count (109/l) 1.75 2.34 1.79 1.79 1.75 1.76 1.83 0.09
B-erythrocytes, MCV (1015/l) 90.0 89.5 88.5 92.5 90.5 89.0 88.5 0.36
Monocyt count (109/l) 0.43 0.56 0.40 0.45 0.40 0.43 0.41 0.60
Neutrophil count (109/l) 3.04 3.71 2.97 3.53 2.88 3.56 3.12 0.41
Erytrocyt count (1012/l) 12.9 13.2 13.0 13.3 13.0 13.1 12.8 0.42
Thrombocyt count (109/l) 252 299 303 262 253 255 245 0.32
*P,0.05; mgA/l, milligrams T. suis-specific antibodies per liter serum; kUA/l, kilo units antibodies per liter serum.
{P-value for a test for homogeneity between trends over time (in mean values) in each severity group. Intersubject correlation was taken into account.
{Each subject had one blood sample drawn during the grass pollen season (May 28 to July 27), and all sampling days were then categorized into 1st period (visit 3 of 9,
n = 8; visit 4 of 9, n = 10) and 2nd period (visit 5 of 9, n = 27; visit 6 of 9, n = 6) to obtain meaningful results by severity subgroups. The mean day of 1st period was day 59
(range 43–69), 2nd period day 90 (range 81–117), and end day 170 (162–185).
{{Calculated for each subjects as total IgE minus the total sum of IgE against T. suis, grass- and birch-allergen.
{{The result of planned analyses (data not shown) executed on the date (March 4, 2009) the study was unblinded.
The placebo group is not shown.
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the allocation at the end of the study that 12 of these cases had
received T. suis eggs [12]. Only one similar decision was made for
a placebo subject, but merely because of one episode (see figure 2,
Placebo) which coincidently was around day 42 and in connection
with asthma symptoms. Taken together, this strongly argues in
favor of a clinically significant side effect in the 12 subjects in the
T. suis group (i.e. 24%). Arguably, the significance of the
gastrointestinal symptoms reported by the further 25 subjects
(76%224%=52%, see figure 2), who did not likewise pause
treatments, may be questioned. However, figure 2 shows that most
of these subjects had a similar pattern of symptoms. Furthermore,
the reason they did not pause treatment was not necessarily that
they did not have significant gastrointestinal symptoms, but simply
that we had not advised that they pause treatment. For example,
we advised only some subjects to pause 2nd treatment, because
early on we were reassured by the observation that subjects 1–2
months ahead of others in treatment schedule rarely had
gastrointestinal symptoms after 3–5 treatments.
We investigated in several ways why only a proportion of
subjects had gastrointestinal side effects after ingestion of T. suis
eggs. Reassuringly, the quality of the egg manufacture did not
explain this. For example, minor dose variation was allowed in the
manufacture, but the variation (2010–2400 eggs) was not
important to the rate of first episodes with side effects. It is
therefore interesting that factors like age, gastrointestinal morbid-
ities, smoking, and allergies did not provide an explanation. We
did not have statistical power to test a role of gender, although we
observed that one of the four included women did report diarrhea
between 2nd and 3rd treatment, and received T. suis eggs (1 of 2
women (50%) vs. 0 of 2 women on placebo, 0%). In the cited
recent clinical trial where five multiple sclerosis patients were
treated with T. suis eggs, three of four women (75%) reported
gastrointestinal symptoms, while the male reported no symptoms
[15].
In explorative analyses we investigated whether the self-reported
gastrointestinal side effects were related to objective measurements
in blood, because such relation could strengthen the validity of
self-reports. In addition, the analysis could help understand risk
factors for gastrointestinal reactions and whether T. suis is expelled
by such reactions. In support of the validity of self-reports, we
observed that the T. suis-IgG response developed faster in subjects
without than with gastrointestinal side effects.
With regards to expulsion, blood parameters that are recognized
effectors in clearance of gastrointestinal helminths (IgE, IgA,
eosinophils) [23–27], did not differ between subjects with and
without gastrointestinal sides effects, despite an overall response to
T. suis. However, such differences could have been difficult to detect
because subjects in general had a low T. suis-IgE response, local
mucosal IgA and eosinophils were not measured, and eosinophil
responses are non-specific and were a result of both T. suis and
allergen exposure (allergic disease). In addition, IgA and IgE have a
shorter serum half life than IgG (,6 vs. 21 days) which may partly
explain the observed concentrations were low. We did not sample
stools and therefore could not measure e.g. copro-antigen, eggs,
larvae, or worms in feces. However, T. suis rarely mature and
produce eggs in aberrant hosts [3,16], and it is therefore not certain
that these measures would document expulsion if there was one. We
speculated that the slower T. suis-IgG response in subjects with
gastrointestinal reactions is suggestive of expulsion of T. suis, because
in single-inoculated pigs serum IgG and IgM antibody responses are
reduced within weeks after documented expulsion [28], and
diarrhoea can be observed in pens when expulsion starts in week
7 (day 51) post-inoculation (authors’ unpublished results). Further-
more, in pigs and mice, one suggested mechanism of expulsion of
Trichuris species is through the IL-4/IL-13 system [29,30], with a
tightly controlled IL-13 induced dramatic elevation in epithelial cell
proliferation and crypt cell hyperplasia that could detach worms
from the intestinal wall [28,31]. It is conceivable that such
histological changes would cause gastrointestinal symptoms. The
reason why the observed gastrointestinal symptoms, and thus
perhaps expulsion, accompanied initial and not later ingestions, is
unclear. At least, expulsion during later ingestions, i.e. correspond-
ing to immunity to T. suis, seems unlikely because the ingestions
induced further antibody responses even in affected subjects, and in
the previous IBD trials they maintained efficacy [4,5,22]. Possible
explanations, however, may involve different immunological
memory (T. suis-specific T cells and antibodies), helminth-induced
immune-suppression (regulatory T-cells, IL-10, TGFb), and/or
histological changes in the intestinal wall [32]. The reason why
symptoms occurred in a proportion of subjects only is also unclear.
If the symptoms were associated with expulsion of T. suis, a genetic
component could be involved because resistance to T. suis infections
has been reported to be different between piglets of different
parental background [33].
Overall, the T. suis-IgG response and other studied factors did
not provide a method to identify subjects at risk of gastrointestinal
side effects, suggesting that it will continue to be a reasonable
precaution to ingest less than 262500 T. suis eggs during the first
42 days when such treatment is tested or prescribed. During longer
treatment (63 to 168 days) with this dose the risk of side effects is
statistically insignificant, also after treatment is stopped (1-year
follow-up data not shown).
Figure 3. Level of serum IgG against adult T. suis excretory/
secretory antigen over time according to severity of gastroin-
testinal symptoms after three-weekly ingestion of infective T.
suis eggs by 49 subjects in a randomized placebo-controlled
double-blind clinical trial in grass-pollen allergic adults, Den-
mark 2008. Within subgroups of severity, data circles are positioned
by severity (None, left; Mild, right), (Moderate, left; Severe, right). Blood
was drawn times 3 (blood visit 1 at start (not shown, no IgG response)),
blood visit 2 during grasspollen season (1st period and 2nd period), and
blood visit 3 at end of study), and diary was kept day 0–168, except in 4
subjects indicated by circles in figure A: 2 subjects (severe) dropped out
(moved abroad, no time) between blood visit 2 (day ,90) and 3,
however recorded diary until day ,90; 2 other subjects (moderate,
severe) recorded diary until blood sampling visit 2 (day ,59) or longer
(.day 90) although they did not attend blood visit 3. * P,0.05.
doi:10.1371/journal.pone.0022346.g003
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In conclusion, during the first two months, ingestions of 2500 T.
suis eggs caused frequent episodes with moderate to severe
gastrointestinal reactions lasting up to two weeks. The response
reflects the initial exposure to the parasite and the associated
immune response. Data from the last four months of the study
suggest that ingestions over longer time mainly provoke a
subclinical stimulation.
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